Investor Presentaiton
52
529
CTLA4 or PD1 + DNA Vaccine Improves Tumor Control
& Survival in Challenge Model
AMERICAN SOCIETY of
Checkpoint Inhibitor Therapies
Combined with INOVIO DNA Medicine
•
Potential to improve response rates, without
adding toxicity
Tumor infiltration of antigen-specific, functional
CD8+ T cells may prime patients for treatment with
checkpoint inhibitors and increase response rates
Combination studies initiated
⚫ MEDI0457 with AstraZeneca PDL-1
• INO-5401 with Regeneron PD-1
• INO-5151 with BMS PD-1 + Celldex FTL3L
(PICI Study)
Molecular Therapy
Original Article
Synergy of Immune Checkpoint Blockade
with a Novel Synthetic Consensus
DNA Vaccine Targeting TERT
GENE & CELL.
THERAPY
Elizabeth K. Duperret, Megan C. Wise, Aspen Trautz, Daniel O. Villarreal, Bernadette Ferraro,² Jewell Walters,²
Jian Yan, Amir Khan, Emma Masteller, Laurent Humeau, and David B. Weiner'
Tumor volume (mm3)
Tumor volume (mm3)
800
600-
400-
200
800-
600-
400-
200
20
10
Days elapsed
-Naive
mTERT alone
MTERT CTLA-4
Naive
mTERT alone
mTERT aPD-1
10
20
Days elapsed
Paper published in Molecular Therapy 2017
INOVIO
POWERING DNA MEDICINESView entire presentation